News

VIPC Awards Commonwealth Commercialization Fund Grant to PS Fertility to Advance Fertility Testing

The Virginia Innovation Partnership Corporation (VIPC) today announced that PS-Fertility, Inc. has been awarded a Commonwealth Commercialization Fund (CCF) grant for $75,000. VIPC’s CCF programs have distributed more than $53 million to Virginia-based startups, entrepreneurs, and university-based inventors since 2012 in support of critical early technology testing and market validation efforts. PS Fertility has also previously received funding from VIPC’s Virginia Venture Partners.

 

Each year in the U.S. alone, approximately 7 million couples seek fertility care. Roughly 50% of infertility is due to the male, yet historically the reasons why are largely a mystery and the diagnostic and treatment burdens have fallen disproportionately on the female. PS Fertility, a clinical diagnostic company spun out of the University of Virginia, is changing the way male fertility testing is conducted with their novel discovery that quantifies the levels of fertilization-competent sperm. Equipped with this information, healthcare providers can better advise couples of the likelihood of fertilization and help guide treatment options.

 

“Our patent-pending technology takes fertility testing to a new level beyond just sperm counting and motility measurement. We can assess the ability of a sperm to fertilize an egg, allowing us to uncover meaningful information about male infertility that’s not currently available through conventional testing. This helps provide couples with insight into their personal fertility journey and improve their ability to conceive,” said Dr. Jeffrey Lysiak, Chief Scientific Officer and Co-Founder of PS Fertility. “CCF grant funding is giving us the opportunity to bring our goal of increasing the number of babies born one step closer to reality. We are grateful for VIPC’s partnership.”

 

With CCF support, PS Fertility will complete the transfer of the technology from UVA to the Charlottesville-based company’s commercial lab. Funding will also enable the startup to finalize the at-home collection test kit and begin offering the solution to patients.

 

“The CCF program has long been about fostering innovative and collaborative efforts in the Commonwealth,” said Jeanette Townsend, VIPC’s Director for Private Sector Grants. “Through VIPC’s grant to PS Fertility, we are not only supporting the commercialization activities of a Virginia startup, but also game-changing technology research and development coming out of the University of Virginia. We could not be more excited to be a part of PS Fertility’s story as they transform fertility testing and shift the industry’s 60-year status quo.”

 

Recent News

04/24/2026

Skyphos Technologies Has Been Awarded its Second U.S. Patent

Skyphos Technologies has been awarded its second U.S. patent, adding to a growing intellectual property portfolio that now includes nearly a dozen patent applications in process around the world. This latest patent secures core technologies and methods that allow micro-scale parts to be produced in seconds, at throughputs designed to exceed legacy manufacturing such as

04/23/2026

CollectiveMinds LLC Places Keith Meadors as Chief Commercial Officer at Genova Diagnostics

CollectiveMinds LLC, a leading executive search firm specializing in life sciences and healthcare, today announced the successful placement of Keith Meadors as Chief Commercial Officer of Genova Diagnostics, a pioneer in advanced diagnostic testing. The appointment marks another milestone for CollectiveMinds in connecting exceptional leadership talent with high-growth organizations across the diagnostics and life sciences

04/22/2026

RIVANNA expands multi-site clinical study for Accuro XV musculoskeletal imaging system

RIVANNA®, developer of AI-enabled clinical decision-support solutions, announced that it has expanded its clinical studies evaluating Accuro® XV, the company’s musculoskeletal imaging system, from two to eight sites nationwide. This expansion follows execution of a funding option by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response